Clinical Trial

A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 27, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum tolerated dose (MTD) and the recommended dose in phase II clinical trials (RP2D); In Phase IIa, to explore the clinical effectiveness and safety of long-term use of RC118 at RP2D doses for patients with different tumor types。
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-01-12; most recent amendment 2025-01-22.
Status change: Not Yet Recruiting → Recruiting 2022-03-21
Trial Details
NCT Number NCT05205850
Lead Sponsor RemeGen Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 135 participants
Start Date 2022-03-03
Primary Completion 2025-09-30 (estimated)
Study Completion 2025-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-01-27